Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study

INTRODUCTION: There is no consensus on whether immune checkpoint inhibitors (ICIs) would offer comparable benefit in mutant-BRAF NSCLC. We, therefore, conducted a study to ascertain the role of ICIs in mutant-BRAF NSCLC. METHODS: Records of 4178 patients and 4462 samples from 15 studies were collect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chenxing, Zhang, Chenyue, Lin, Jiamao, Li, Zhenxiang, Wang, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474360/
https://www.ncbi.nlm.nih.gov/pubmed/34589911
http://dx.doi.org/10.1016/j.jtocrr.2020.100006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474360/
https://www.ncbi.nlm.nih.gov/pubmed/34589911
http://dx.doi.org/10.1016/j.jtocrr.2020.100006

Ejemplares similares